Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials

Two placebo-controlled Phase III trials have failed to demonstrate any benefit for aztreonam solution for inhalation on Quality of Life-Bronchiectasis Respiratory Symptoms scores in patients with non-cystic fibrosis bronchiectasis and Gram-negative bacterial colonisation.